MTAP and neoplasm: Notably, MTAP‐deficient tumors caused MTA accumulation in the tumor microenvironment, which impaired T‐cell function through PRMT5 inhibition and adenosine receptor agonism in T‐cells, ultimately attenuating the effects of immune checkpoint inhibitors [38].